近日，上海复星医药（集团）股份有限公司与专注于神经退行性疾病领域的韩国生物制药公司AriBio共同宣布，双方在前期合作的基础上，就阿尔茨海默病创新药AR1001的开发、注册、生产和商业化等的权利，签署了全球独家选择权协议。

本次交易采用“选择行权费+许可费支付”的模式，复星医药将向AriBio支付6000万美元的选择权费，并有权于约定行权期限内决定是否行权；选择行权后，复星医药将支付至多1.8亿美元的首付款和监管里程碑付款；当许可产品年销售额达到至少25亿美元，将触发销售里程碑付款。

随着本次协议的签署，双方的合作将拓展至全球包括美国、欧洲和日本等关键市场。未来，双方将依托复星医药在临床开发、生产、注册申报及商业化的成熟能力，加速推进药物全球落地。

中韩生物医药产业联动不断升温之际，与复星医药达成BD交易的AriBio，将亮相BIOCHINA Global Forum @ Korea。AriBio董事总经理Fred Kim将参与创新药跨境合作模式圆桌对谈，分享Biotech管线价值挖掘、跨境BD谈判与全球商业化布局的实战经验，为中韩创新药产业合作探寻全新路径与前景。

BIOCHINA Global Forum @ Korea将于7月9-10日在韩国首尔举行，以论坛、约见、路演、活动四大板块打造中韩合作交流平台，直达韩国 Biotech 企业决策层。

目前，诺和诺德、勃林格殷格翰、AriBio、Alteogen、AIMED BIO、NKGen Biotech、Rznomics、AbTis、KIMCo、KDDF等跨国药企、韩国药企及行业协会高层已确认参会。

同时，原启生物、威斯津生物、博生吉医药、友芝友生物、科济药业、博锐生物、华奥泰生物、天广实生物、启德生物、艾科联生物科技等国内头部biotech高层也积极参与，中韩产业伙伴携手共探跨境合作新机遇。

依托行业深度交流契机，本次盛会全日程正式首度公开，助力中韩药企提前布局跨境合作机遇。

BIOCHINA Global Forum @ Korea 2026

全日程 

Day 1 – July 9 | Morning

BD & Collaboration Between China and Korea

09:00–09:10Opening Remarks – Organizer and Local Partners

Welcome address introducing the forum objectives and China–Korea collaboration opportunities

09:10–09:30Keynote Presentation – China & Korea Biotech and Pharma Market Landscape

Overview of China and Korea biotech markets: size, policy, regulatory environment, clinical ecosystem, innovation trends, and BD opportunities.

Speaker: Ellen Jooyeon Kim, Korea Drug Development Fund (KDDF), Director, Global Partnership & Business Development Division

09:30–10:10Panel Discussion – China–Korea Collaboration Opportunities and Investment Trends

Discussion on cross-border collaboration models, VC priorities, emerging technologies (ADC, CGT, AI-driven drug discovery), and partnership structuring.

Moderator: Ellen Jooyeon Kim, Korea Drug Development Fund (KDDF), Director, Global Partnership & Business Development Division

Panelist: Jielun Zhu, Excalipoint Therapeutics , Co-Founder, CFO & CBO

10:10–10:30Tea Break and Networking

10:30–11:10Panel Discussion – BD Deals and Licensing Case Studies – MNCs and big pharma

Insights on recent China–Korea licensing deals and strategic partnerships: deal structures, collaboration models, and lessons learned.

Moderator: Kevin Huh, KIMCo, CEO

Panelists: Jenny Yang, Novo Nordisk, Head of External Innovation Asia Pacific

June Hahn, Boehringer Ingelheim, Head of BD&L Korea

11:10–12:00Panel Discussion – Innovative Collaboration Models of Biotech

Moderator: Jielun Zhu, Excalipoint Therapeutics , Co-Founder, CFO & CBO

Panelists: Peng Zang, CARSgen, Vice President, Strategic Planning, Head of Business Development

Gang Qin, GeneQuantum, CEO

Fred Kim, AriBio, Managing Director

Day 1 – July 9 | Afternoon

Innovative Therapeutics & R&D Collaboration – Antibody Drugs and XDCs

13:00–13:20Keynote Presentation – M701 (EpCAM×CD3): A Novel T-Cell Engager for Malignant Ascites and Pleural Effusion

Speaker: Zhou Pengfei, WUHAN YZY BIOPHARMA CO., LTD., Founder& Chairman &CEO

13:20–13:40Keynote Presentation – Development of Novel Bispecific Antibody (BsAb) Molecules

Speaker: Xiangyang Zhu, Shanghai Huaota Biopharmaceutical Co., Ltd., CEO

13:40-14:00Keynote Presentation – Subcutaneous delivery of ADC by use of ALT-B4; Novel Hyaluronidase

Speaker: Sun Bae Lee, Alteogen, Senior Vice President

14:00-14:20Keynote Presentation – Design and Development of Dual-Payload and Bispecific ADCs

Speaker: Nam Gu Her, AIMED BIO, CEO

14:20-14:40Keynote Presentation – AT-211 ADC targeting CLDN18.2 for gastric cancersprepared by AbClick, a site-selective linker

Speaker: Sang Jeon Chung, AbTis Co. Ltd., CSO

14:40-15:00Keynote Presentation – High-Concentration Antibody Formulation

15:00-15:20 Keynote Presentation – Antibody Process Development and PPQ Validation

15:20-15:40Tea Break and Networking

15:40-16:20Panel Discussion-Accelerating the Bispecific Antibody & XDC Race：Global Landscape with Korea Focus and Differentiation Strategies

16:20-17:00Panel Discussion-Accelerating the Biospecific Antibody & XDC Race：Global Landscape with China Focus and Differentiation Strategies

Panelist : Gang Qin, GeneQuantum, CEO

Day 2 – July 10 | Morning

Global Clinical Development

9:00-10:00From Clinical Trials to Market – The CRO Acceleration Path – open for sponsorship

End-to end Clinical Development Support

Fast-track Strategies for regulatory approval

Case studies of successful global collaborations

Enabling biotech companies to shorten time-to market

10:00-11:00Navigating Korea’s Clinical Development Landscape and Opportunities

Korea Clinical Trial Ecosystem & Regulatory Pathway

Strategic Advantages of Conducting Clinical Trials in Korea

11:00-12:00CMO Perspectives on Global Clinical Development

How Chinese Biopharma CMOs Drive Global Clinical Development

Global Clinical Development Strategies: Insights from Chinese Biopharma CMOs

Panelist: Wei Zhu, BioRay Pharmaceutical Co., Ltd., Chief Medical Officer

Jinjin Liang, Beijing Mab-Works Co Ltd., Chief Medical Officer

12:00-13:00Lunch

Day2–July10 | Afternoon

Cell & Gene Therapy

Innovations & R&D Collaboration

13:00–13:20Keynote Presentation–Advances in In Vivo CAR Breakthrough in Lentiviral Vector-based in vivo CAR Technology

Speaker:Lin Yang,PersonGen BioTherapeutics(Suzhou) Co.,Ltd. Founder, Chairman, CEO

13:20–13:40Keynote Presentation – Technology advancement and clinical application of CAR-T Cell Therapy

Speaker:Zonghai Li, CARsgen, Founder &CEO

13:40-14:00Keynote Presentation – Use of Troculeucel (Cryopreserved Enhanced Autologous NK Cell Therapy) for Neurodegenerative Diseases.

Speaker: Paul Song, NKGen Biotech, Inc., Chairman and CEO

14:00-14:20Tea Break and Networking

14:20-14:40Keynote Presentation – Next-generation CAR-T therapeutics for precision medicine.

Speaker: Xiaowen He, Oricell Therapeutics Co.,Ltd, Co-founder and Chief Scientific Officer

14:40-15:00Keynote Presentation – RNA Editing Therapeutics through Catalytic RNA Rewriting: From Platform to Clinic

Speaker: Seong-Wook Lee,Rznomics Inc, President & CEO

15:00-15:20 Keynote Presentation –From mRNA Cancer Vaccines to In Vivo CAR-T: Delivery-Driven Innovation and Clinical Translation

Speaker: Xiangrong Song, WestGene Biopharma Co., Ltd, CEO

15:20-15:40Panel Discussion – Korea CGT Panel

15:40-16:20Panel Discussion–Future Directions in CGT Technology

Moderator: Lin Yang, PersonGen BioTherapeutics (Suzhou) Co., Ltd. Founder, Chairman, CEO

Panelist: Xiaowen He, Oricell Therapeutics Co.,Ltd, Co-founder and Chief Scientific Officer

16:20-16:40Keynote Presentation：From Process Development to Commercial Supply: China’s Integrated CMC Manufacturing Solutions

16:40-17:00Keynote Presentation： Korea’s Excellence in Bio-manufacturing: Advanced CMC and Quality Strategies